Table 1:

Clinical characteristics of patients and their systemic disease

	eye 1	eye 2	eyes 3 + 4	eye 5	eye 6	eyes 7 + 8	eye 9	eye 10	eye 11	eyes 12 + 13	eyes 14
age (years), gender	66, F	88, F	88, M	64, F	23, M	64, F	69, M	66, M	37, F	72 F	78 M
prior treatment	nivolumab, vemurafenib	none	none	none	interluekin-2, vemurafenib	none	Ipilimumab, nivolumab	None	lnterleukin-2	Pembrolizumab	none
drug at time ocular symptoms	Ipilimumab	Ipilimumab, Nivolumsb	Nivolumab	Pembrolizumab	ipilimumab	none	Nivolumab	Pembrolizumab	Autologous anti-tumor lymphocyte tx	Encorafenib + Binimetinib	none
CNS mets*	no	Yes (pre)	no	yes (post)	yes (pre)	Yes (pre)	no	no	yes (post)	yes (post)	no
other metastatic sites	subcutaneous, pulmonary, small intestine, colon,	LN, pulmonary, small intestine, spleen	subcutaneous, LN	LN, pulmonary	subcuteanous, LN, pulmonary	none	LN, pulmonary	pulmonary	chest wall	LN, adrenal	subcutaneous
follow up (mos) **	63	22	5	3	70	33	23	5	97	2	43
vital status	dead	alive	alive	dead	alive	alive	alive	alive	alive	dead	alive
genomics of CutMM	BRAF	NRAS,TERT	NRAS	NRAS	BRAF	BRAF	BRAF wild type	Not available	BRAF	BRAF	BRAF wild type

^*= “pre” refers to CNS disease prior to ophthalmic diagnosis and “post” refers to CNS disease following ophthalmic diagnosis

^**= time from ocular diagnosis to death or last follow up, M = male, F = female, CNS mets = central nervous system metastasis, tx = treatment, LN = lymph node, mos = months, CutMM = cutaneous malignant melanoma, BRAF = proto-oncogene B-Raf, NRAS = Neuroblastoma RAS viral oncogene homolog, TERT = Telomerase reverse transcriptase